Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Viracta Therapeutics To Reprioritize Resources To Focus On Nana-val Development Program In Relapsed Or Refractory EBV-Positive Peripheral T-Cell Lymphoma; Announces 42% Force Reduction, Sees $700K In Total Expenses

Author: Benzinga Newsdesk | November 06, 2024 06:32pm

Posted In: VIRX